Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmesartan medoxomil/hydrochlorothiazide 20/25 mg versus 40/25 mg in patients with essential hypertension inadequately controlled on olmesartan medoxomil 40 mg
2006-003877-28Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of olmesartan and hydrochlorothiazide in essential hypertension (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in mean trough sitting diastolic blood pressure at Week 8. Started Sep 2006; status: completed.
02
Drugs
olmesartanhydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2006-003877-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003877-28.